Legend Biotech Announces Participation in Upcoming Investor Conference
May 11 2023 - 4:01PM
Business Wire
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a
global biotechnology company developing, manufacturing and
commercializing novel therapies to treat life-threatening diseases,
today announced it will participate in the 2023 RBC Capital Markets
Global Healthcare Conference in New York City. Ying Huang, PhD, CEO
of Legend Biotech, will participate in a fireside chat on
Wednesday, May 17, 2023 at 9:30 a.m. (Eastern Time).
About Legend Biotech
Legend Biotech is a global biotechnology company dedicated to
treating, and one day curing, life-threatening diseases.
Headquartered in Somerset, New Jersey, we are developing advanced
cell therapies across a diverse array of technology platforms,
including autologous and allogenic chimeric antigen receptor T-cell
and natural killer (NK) cell-based immunotherapy. From our three
R&D sites around the world, we apply these innovative
technologies to pursue the discovery of cutting-edge therapeutics
for patients worldwide.
Learn more at www.legendbiotech.com and follow us on Twitter and
LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230511005661/en/
Investor Contacts: Joanne Choi, Senior Manager, Investor
Relations, Legend Biotech joanne.choi@legendbiotech.com
Crystal Chen, Manager, Investor Relations, Legend Biotech
crystal.chen@legendbiotech.com
Press Contact: Tina Carter, Corporate Communications
Lead, Legend Biotech tina.carter@legendbiotech.com (908)
331-5025
Legend Biotech (NASDAQ:LEGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Legend Biotech (NASDAQ:LEGN)
Historical Stock Chart
From Apr 2023 to Apr 2024